Akèy › Melanom › Texas › Dallas
Etid klinik pou Melanom nan Dallas, TX
20 etid pou Melanom ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Dallas
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Ap rekriteFaz 3
- Texas Oncology - Medical City, Dallas
- Texas Oncology, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Baylor, Scott and White Research Institute, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Ap rekriteFaz 1/2
- UT Southwestern, Dallas
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Texas Oncology - Dallas SCRI, Dallas
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- Texas Oncology, P.A., Dallas
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Ap rekriteFaz 1/2
- Call for Information (Investigational Site 0054), Dallas
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Mary Crowley Cancer Research, Dallas
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Ap rekriteFaz 3
- Texas Retina Associates - Dallas, Dallas
- University of Texas Southwestern Medical Center-5323 Harry Hines Blvd, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
Ap rekriteFaz 1
- Mary Crowley Cancer Research, Dallas
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- UT Southwestern Medical Center, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Dallas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Dallas, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Dallas
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Mary Crowley Cancer Research, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Dallas, Dallas
Etid Melanom nan lòt vil
- Houston, TX59 etid
- New York City, NY38 etid
- Los Angeles, CA34 etid
- Nashville, TN33 etid
- Pittsburgh, PA31 etid
- Boston, MA26 etid
- Philadelphia, PA23 etid
- San Francisco, CA22 etid
- Durham, NC21 etid
- Atlanta, GA21 etid
- St. Louis, MO21 etid
- Salt Lake City, UT21 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè vejik27 etid
- Kansè poumon27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.